Abstract
Chemotherapy is important part of the systemic treatment of non-small cell lung cancer (NSCLC). Vinorelbine has proven its effectiveness in adjuvant therapy, as part of chemoradiotherapy programs, and in the treatment of metastatic disease. The oral form of the drug is significantly more convenient to use and can be used not only in standard dosage regimens (both in monotherapy and in combination with platinum derivatives), but also in metronomic therapy, which provides for more frequent administration of vinorelbine in smaller single doses. Oral vinorelbine has been shown to be highly effective and safe in various patient populations, including subgroups of elderly and patients with ECOG2, and can be widely used in various stages of NSCLC treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
